elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q46780069-D70B6237-322F-4AFD-B0AD-F3FEC2CC98C3
Q46780069-D70B6237-322F-4AFD-B0AD-F3FEC2CC98C3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q46780069-D70B6237-322F-4AFD-B0AD-F3FEC2CC98C3
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
P2860
Q46780069-D70B6237-322F-4AFD-B0AD-F3FEC2CC98C3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q46780069-D70B6237-322F-4AFD-B0AD-F3FEC2CC98C3
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2d0f5700f560969018a98c8893e2df2142dc3bb7
P2860
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.